CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2008-05-11 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −48,370 | 203,223 | ||
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +200 | $2.83 | $566 | 9,766,473 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +100 | $2.84 | $284 | 9,766,573 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +300 | $2.85 | $855 | 9,766,873 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +1,400 | $2.87 | $4K | 9,768,273 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +800 | $2.89 | $2K | 9,769,073 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +700 | $2.90 | $2K | 9,769,773 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +3,000 | $2.91 | $9K | 9,772,773 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +1,000 | $2.92 | $3K | 9,773,773 |
| 2008-03-11 | FROST PHILLIP MD ET AL 10% owner | Purchase | +2,500 | $2.94 | $7K | 9,776,273 |
| 2008-02-25 | Yossi Maimon VP, Chief Financial Officer | Sale | −33,300 | $3.18 | $106K | 26,700 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Option exercise | +86,176 | $0.97 | $84K | 86,176 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Shares withheld for taxes | −26,176 | $3.20 | $84K | 60,000 |
| 2008-02-22 | Yossi Maimon VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −86,176 | 533,796 | ||
| 2008-02-07 | Kornberg Roger D. Director | Grant or award · Stock Options (Right to Buy) | +50,000 | 50,000 | ||
| 2008-02-07 | Aviezer David President & CEO | Grant or award · Stock Options (Right to Buy) | +600,000 | 600,000 | ||
| 2008-02-07 | Yossi Maimon VP, Chief Financial Officer | Grant or award · Stock Options (Right to Buy) | +175,000 | 175,000 | ||
| 2008-02-07 | Almon Einat Brill VP, Product Development | Grant or award · Stock Options (Right to Buy) | +311,272 | 311,272 | ||
| 2008-02-07 | Shaaltiel Yoseph Executive VP, R&D | Grant or award · Stock Options (Right to Buy) | +263,728 | 263,728 | ||
| 2007-12-19 | Shaaltiel Yoseph Executive VP, R&D | Purchase | +4,800 | $3.40 | $16K | 2,974,107 |
Page 31 of 33 · 654 trades